Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Which ASX health stocks might get FDA approval in 2023?

It is the dream of many ASX health stocks and their investors for their company's device or drug to be approved by the FDA, the USA's medical regulator. This is because it unlocks the world's largest healthcare market. Companies that achieved that feat recently included hearing aid company Nuheara (ASX:NUH), along with infant formula stocks A2…

ByNick SundichDecember 22, 2022

Immutep (ASX: IMM) has massive potential!

Immutep ( ASX: IMM ) develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. It has several product candidates at different phases of clinical trials. But its lead product candidate is Eftilagimod Alpha (Efti), a recombinant protein that is in phase 2b clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. …

ByMarc KennisNovember 30, 2022

Actinogen Medical (ASX: ACW): Good news on phase 2 trials can catapult this stock

Working on a new drug for Alzheimer’s disease Actinogen Medical (ASX: ACW) is a Sydney-based biotechnology company working on finding treatments for Alzheimer’s and other neurological diseases. It’s working on a number of drugs, but its Xanamem’s recent clinical developments are what’s got the market excited. No time to do stock research,…

ByMarc KennisSeptember 29, 2022

Pfizer delivers the goods on a COVID-19 vaccine

10 November 2020 One of the reasons investors can be optimistic about 2021 is the speed with which the first of the Covid-19 vaccines delivered Phase 3 data. On Monday 9 November the American pharmaceutical major Pfizer (NYSE: PFE) announced the results of an interim analysis showing that the BNT162b2 vaccine was more than 90% effective…

ByMarc KennisNovember 10, 2020